Abstract
To offer more tailored treatment to individual patients with squamous cell carcinoma of the vulva, more accurate prediction of lymph node metastases is required. As p53 and mdm2 are genes known to be involved in the development of other tumours, we studied expression of p53 and mdm2 in carcinogenesis of squamous cell carcinoma of the vulva and their clinical relevance. Archival material of 141 T1 and T2 vulvar tumours were used. Of the 141 primary tumours, the corresponding 39 lymph node metastases (LNM) were studied, and in 90 cases the pre-existent epithelia adjacent to the tumour (EAT) and in 14 cases vulvar intraepithelial neoplasia adjacent to the tumour (VIN) was also investigated. Detection of p53 and mdm2 protein was immunohistochemically performed. Scoring categories were: negative (1); weakly positive (2); moderately to markedly positive (3); and markedly positive (4). Overexpression of p53 was seen in 56% of the LNM, 39% of the primary tumours, 21% of the VIN lesions and 0% in the group of EAT. No relation was found between overexpression of p53 in the primary tumour and LNM. Expression of mdm2 was seen in 14% of the primary tumours, of which four cases were marked positive. In the group of LNM no mdm2-positive staining was observed. In the group of EAT, 25% was mdm2-positive, of which six cases were marked positive. In the group of VIN, 36% showed moderate (score 3) mdm2 expression. No relation was found between expression of mdm2 and LNM. In squamous cell carcinoma, overexpression of p53 is a late event in carcinogenesis. Marked expression of mdm2 is rarely seen in vulvar carcinomas, indicating that aberrant p53 cannot induce mdm2 expression. LNM cannot be predicted by detection of these proteins.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Barak, Y., Juven, T., Haffner, R. & Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461–468.
Bosari, S. & Viale, G. (1995) The clinical significance of p53 aberrations in human tumors. Virchows Arch 427: 229–241.
Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A. K. & Coggi, G. (1995) p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 147: 790–798.
Charpin, C., Devictor, B., Andrac, L., Amabile, J., Bergeret, D., Allasia, C. & Piana L and LaVaut, M. N. (1995) p53 quantitative immunocytochemical analysis in breast carcinomas. Hum Pathol 26: 159–166.
Chu, J., Tamimi, H., Ek, M. & Figge, D. (1982) Stage I vulvar cancer: criteria for microinvasion. Obstet Gynecol 59: 716–719.
Coulter, L. K., Wolber, R. & Tron, V. A. (1995) Site-specific comparison of p53 immunostaining in squamous cell carcinomas. Hum Pathol 26: 531–533.
Dazard, J., Augias, D., Neel, H., Mils, V., Marechal, V., Basset-Seguin, N. & Piette, J. (1997) Mdm2 protein is expressed in different layers of normal human skin. Oncogene 14: 1123–1128.
Emanuels, A., Hollema, H., Suurmeyer, A. & Koudstaal, J. (1994) A modified method for antigen retrieval MIB-1 staining of vulvar carcinoma. Eur J Morphol 32: 335–337.
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. & Cote, R. J. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer [see comments]. N Engl J Med 331: 1259–1264.
Esrig, D., Spruck, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A. & Cote, R. J. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389–1397.
Florenes, V. A., Oyjord, T., Holm, R., Skrede, M., Borresen, A. L., Nesland, J. M. & Fodstad, O. (1994) TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 69: 253–259.
Hartwell, L. H. & Kastan, M. B. (1994) Cell cycle control and cancer. Science 266: 1821–1828.
Kagie, M., Kenter, G., Tollenaar, R., Hermans, J., Baptist Trimbos, J. & Fleuren, G. (1997) p53 protein overexpression is common and independent of human papillomavirus infection in squamous cell carcinoma of the vulva. Cancer 80: 1228–1233.
Kennedy, S. M., Macgeogh, C., Jaffe, R. & Spurr, N. K. (1994) Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations [see comments]. Hum Pathol 25: 438–442.
Kessis, T. D., Slebos, R. J., Han, S. M., Shah, K., Bosch, X. F., Munoz, N., Hedrick, L. & Cho, K. R. (1993) p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol 143: 1398–1405.
King, L. A., Okagaki, T., Gallup, D. G., Twiggs, L. B., Messing, M. J. & Carson, L. F. (1996) Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis. Gynecol Oncol 61: 227–232.
Kohlberger, P., Kainz, C., Breitenecker, G., Gitsch, G., Sliutz, G., Kolbl, H., Tschachler, E. & Reinthaller, A. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer 76: 1786–1789.
Lane, D. P. (1992) p53, guardian of the genome. Nature 358: 15–16.
Lassam, N. J., From, L. & Kahn, H. J. (1993) Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53: 2235–2238.
Marchetti, A., Buttitta, F., Pellegrini, S., Merlo, G., Chella, A., Angeletti, C. A. & Bevilacqua, G. (1995) mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4: 93–97.
McCann, A. H., Kirley, A., Carney, D. N., Corbally, N., Magee, H. M., Keating, G. & Dervan, P. A. (1995) Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71: 981–985.
Milde-Langosch, K., Albrecht, K., Joram, S., Schlechte, H., Giessing, M. & Loning, T. (1995) Presence and persistence of HPV infection and p53 mutation in cancer of the cervix and the vulva. Int J Cancer 63: 639–645.
Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245.
Ofner, D., Maier, H., Riedmann, B., Holzberger, P., Nogler, M., Totsch, M., Bankfalvi, A., Winde, G., Bocker, W. & Schmid, K. (1995) Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol Mol Pathol 48: 12–16.
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. & Vogelstein, B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas [see comments]. Nature 358: 80–83.
Prokocimer, M. & Rotter, V. (1994) Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84: 2391–2411.
Przygodzki, R. M., Finkelstein, S. D., Langer, J. C., Swalsky, P. A., Fishback, N., Bakker, A., Guinee, D. G., Koss, M. & Travis, W. D. (1996) Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 148: 1531–1541.
Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P. & Peyrat, J. P. (1994) MDM2 gene amplification in human breast cancer. Eur J Cancer 30A: 982–984.
Shurbaji, M. S., Kalbfleisch, J. H. & Thurmond, T. S. (1995) Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26: 106–109.
Sun, X. F., Carstensen, J. M., Zhang, H., Stal, O., Wingren, S., Hatschek, T. & Nordenskjold, B. (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369–1373.
Vogt, T., Zipperer, K. H., Vogt, A., Holzel, D., Landthaler, M. & Stolz, W. (1997) p53-protein and Ki-67 antigen expression are both reliable biomarkers of prognosis in thick stage 1 nodular melanomas of the skin. Histopathology 30: 57–63.
Wu, X., Bayle, J., Olson, D. & Levine, A. (1993) The p53-mdm2 autoregulatory feedback loop. Genes Dev 7: 1126–1132.
Xerri, L., Bouabdallah, R., Camerlo, J. & Hassoun, J. (1994) Expression of the p53 gene in Hodgkin’s disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol 25: 449–454.
Younes, M., Lebovitz, R. M., Bommer, K. E., Cagle, P. T., Morton, D., Khan, S. & Laucirica, R. (1995) p53 accumulation in benign breast biopsy specimens. Hum Pathol 26: 155–158.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Emanuels, A., Koudstaal, J., Burger, M. et al. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases. Br J Cancer 80, 38–43 (1999). https://doi.org/10.1038/sj.bjc.6690318
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690318
Keywords
This article is cited by
-
Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma
British Journal of Cancer (2003)
-
Loss in 3p and 4p and Gain of 3q Are Concomitant Aberrations in Squamous Cell Carcinoma of the Vulva
Modern Pathology (2001)